中国药业2025，Vol.34Issue(8)：25-28,4.DOI:10.3969/j.issn.1006-4931.2025.08.006
我国药品集采政策对非PCI治疗冠心病患者预后的影响
Effect of Drug Centralized Procurement Policy on the Prognosis of Patients with Coronary Heart Disease Treated with Non-PCI in China
摘要
Abstract
Objective To explore the effect of original drugs and generic drugs on the prognosis of patients with non-percutaneous coronary interventional treatment of coronary atherosclerotic heart disease(refered as coronary heart disease)before and after the implementation of drug centralized procurement policy.Methods Patients with coronary heart disease diagnosed by coronary angiography who were hospitalized in the hospital from January 2017 to December 2018(before the implementation of drug centralized procurement policy)and from January 2020 to December 2021(after the implementation of drug centralized procurement policy)were selected respectively,with 230 patients in each group,which as the control group and the observation group respectively,196 cases and 184 cases were actually included after excluding the patients who were lost to follow-up and self-withdrawal.Follow-up(via telephone or outpatient visit)was conducted every six months after discharge.The primary endpoints were angina pectoris,myocardial infarction or unplanned revascularization,hospitalization for heart failure,stroke,cardiac death and all-cause death.The secondary endpoints were composite cardiovascular adverse events(sum of the main observation endpoint).Cox regression analysis was used to compare the incidence of adverse cardiovascular events between the two groups.Results The proportion of males,smoking and drinking,heart rate,the level of triglyceride(TG),utilization rate of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker(AECI/ARB),clopidogrel,ticagrelor and nitrates in the observation group were significantly higher than those in the control group(P<0.05),and the level of high density lipoprotein cholesterol(HDL-C)was significantly lower than that in the control group(P<0.05).Log-Rank test showed that there was no significant difference in the incidence of angina pectoris and combined cardiovascular adverse events between the two groups(P>0.05).Multivariate Cox regression analysis showed that there was no significant difference in the incidence of angina pectoris and composite cardiovascular adverse events between the two groups(P>0.05).Conclusion There was no significant increase in the incidence of adverse cardiovascular events in patients with coronary heart disease after the implementation of the drug centralized procurement policy,but the quality and adverse reactions of the generic drugs of winning the bidding should be continuously monitored.关键词
药品集中采购/经皮冠状动脉介入/冠心病/预后Key words
drug centralized procurement policy/percutaneous coronary intervention/coronary heart disease/prognosis分类
医药卫生引用本文复制引用
连晓清,徐崇利,韦伟,周本军,王腾蛟,高世友,张志华..我国药品集采政策对非PCI治疗冠心病患者预后的影响[J].中国药业,2025,34(8):25-28,4.基金项目
南京医科大学附属江宁医院青年创新科研基金重点项目[JNYYZXKY202112]. （）
